Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
Bio-Techne (NASDAQ: TECH) has announced the launch of new AI-engineered designer proteins through its R&D Systems brand. The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available in both RUO and GMP formats), and three Wnt/RSPO Agonist proteins.
These innovative proteins are specifically engineered using advanced AI-based design platforms and protein evolutionary workflows to enhance cellular therapy processes and research applications. The products feature improved functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability, leveraging generative AI trained on nearly five decades of proteomic leadership.
The new proteins are designed to address critical needs in cell culture performance and optimization, particularly in cellular therapy applications, stem cell research, organoid development, and regenerative medicine.
Bio-Techne (NASDAQ: TECH) ha annunciato il lancio di nuove proteine progettate tramite intelligenza artificiale attraverso il suo marchio R&D Systems. Il portafoglio ampliato include IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (disponibili sia in formato RUO che GMP) e tre proteine agoniste Wnt/RSPO.
Queste proteine innovative sono specificamente progettate utilizzando piattaforme di design avanzate basate su intelligenza artificiale e flussi di lavoro evolutivi delle proteine per migliorare i processi di terapia cellulare e le applicazioni di ricerca. I prodotti offrono funzionalità migliorate come iperattività, affinità per i recettori potenziate e stabilità al calore migliorata, sfruttando l'AI generativa addestrata su quasi cinque decenni di leadership proteomica.
Le nuove proteine sono progettate per affrontare esigenze critiche nelle prestazioni della coltura cellulare e nell'ottimizzazione, in particolare nelle applicazioni di terapia cellulare, nella ricerca sulle cellule staminali, nello sviluppo di organoidi e nella medicina rigenerativa.
Bio-Techne (NASDAQ: TECH) ha anunciado el lanzamiento de nuevas proteínas diseñadas con inteligencia artificial a través de su marca R&D Systems. El portafolio ampliado incluye IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (disponibles en formatos RUO y GMP) y tres proteínas agonistas Wnt/RSPO.
Estas proteínas innovadoras están diseñadas específicamente utilizando plataformas de diseño avanzadas basadas en inteligencia artificial y flujos de trabajo evolutivos de proteínas para mejorar los procesos de terapia celular y las aplicaciones de investigación. Los productos presentan funcionalidades mejoradas como hiperactividad, afinidades receptoras incrementadas y mejor estabilidad al calor, aprovechando la IA generativa entrenada en casi cinco décadas de liderazgo proteómico.
Las nuevas proteínas están diseñadas para abordar necesidades críticas en el rendimiento y la optimización de cultivos celulares, especialmente en aplicaciones de terapia celular, investigación de células madre, desarrollo de organoides y medicina regenerativa.
Bio-Techne (NASDAQ: TECH)는 R&D Systems 브랜드를 통해 인공지능으로 설계된 새로운 디자인 단백질을 출시했다고 발표했습니다. 확장된 포트폴리오에는 IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (RUO 및 GMP 형식 모두 제공)과 세 가지 Wnt/RSPO Agonist 단백질이 포함됩니다.
이 혁신적인 단백질들은 세포 치료 프로세스와 연구 응용 프로그램을 향상시키기 위해 고급 인공지능 기반 디자인 플랫폼과 단백질 진화 워크플로우를 사용하여 특별히 설계되었습니다. 이 제품들은 하이퍼 활동성, 수용체 친화성 증가, 그리고 개선된 열 안정성 같은 향상된 기능을 가지고 있으며, 거의 50년의 단백질학 리더십을 통해 훈련된 생성적 AI를 활용하고 있습니다.
새로운 단백질들은 세포 배양 성능 및 최적화의 중요한 요구를 충족하기 위해 설계되었으며, 특히 세포 치료 응용, 줄기세포 연구, 오르가노이드 개발, 그리고 재생 의학 분야에서 중요한 역할을 하고 있습니다.
Bio-Techne (NASDAQ: TECH) a annoncé le lancement de nouvelles protéines designer conçues par intelligence artificielle via sa marque R&D Systems. Le portefeuille élargi comprend IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (disponibles en formats RUO et GMP) ainsi que trois protéines agonistes Wnt/RSPO.
Ces protéines innovantes sont spécifiquement conçues à l'aide de plateformes de conception avancées basées sur l'intelligence artificielle et de flux de travail évolutifs des protéines pour améliorer les processus de thérapie cellulaire et les applications de recherche. Les produits présentent des fonctionnalités améliorées telles que l'hyperactivité, des affinités pour les récepteurs accrues et une meilleure stabilité à la chaleur, tirant parti de l'IA générative entraînée sur près de cinq décennies de leadership en protéomique.
Les nouvelles protéines sont conçues pour répondre à des besoins critiques en matière de performance et d'optimisation des cultures cellulaires, en particulier dans les applications de thérapie cellulaire, la recherche sur les cellules souches, le développement d'organoïdes et la médecine régénérative.
Bio-Techne (NASDAQ: TECH) hat die Einführung neuer, mithilfe von KI entwickelter Designer-Proteine unter der Marke R&D Systems bekannt gegeben. Das erweiterte Portfolio umfasst IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (verfügbar in RUO- und GMP-Formaten) sowie drei Wnt/RSPO Agonisten-Proteine.
Diese innovativen Proteine sind speziell mit fortschrittlichen KI-basierten Designplattformen und evolutionären Proteinarbeitsabläufen entwickelt worden, um die Zelltherapieprozesse und Forschungsanwendungen zu verbessern. Die Produkte zeichnen sich durch verbesserte Funktionen wie Hyperaktivität, erhöhte Rezeptoraffinitäten und verbesserte Wärmebeständigkeit aus, wobei generative KI genutzt wird, die auf fast fünf Jahrzehnten proteomischer Führerschaft trainiert wurde.
Die neuen Proteine sind dazu konzipiert, kritische Anforderungen an die Zellkulturleistung und -optimierung zu erfüllen, insbesondere in der Zelltherapie, der Stammzellenforschung, der Organoidentwicklung und der regenerativen Medizin.
- Launch of new AI-engineered protein portfolio expanding product offerings
- Dual availability of FGF basic Heat Stable in both RUO and GMP formats, enabling research and therapeutic applications
- Products feature enhanced functionalities including improved stability and performance
- None.
Insights
The launch of AI-engineered designer proteins represents a strategic expansion in Bio-Techne's high-margin protein portfolio. The new proteins, particularly the IL-2 Heat Stable Agonist and FGF basic Heat Stable variants, address critical bottlenecks in cell therapy manufacturing where stability and performance are paramount. The dual availability of research (RUO) and GMP-grade products creates a complete commercial ecosystem, enabling seamless transition from research to clinical applications.
The integration of AI-driven design with Bio-Techne's extensive proteomic data represents a significant competitive advantage. This technological leap could potentially reduce development costs while improving product performance metrics. The Wnt/RSPO agonist series specifically targets the rapidly growing organoid market, estimated to reach
The enhanced thermal stability and modified receptor affinity of the new IL-2 variant addresses a major pain point in CAR-T manufacturing, where protein stability directly impacts production costs and therapy efficacy. The hyperactive Activin A could significantly improve differentiation protocols, potentially reducing manufacturing timelines and costs for regenerative medicine products.
The GMP-grade FGF basic Heat Stable protein is particularly noteworthy as it can support scaled-up manufacturing of cell therapies - a critical consideration as more products move toward commercialization. These improvements in protein stability and functionality could translate to reduced production costs and improved yields in cell therapy manufacturing, directly impacting the bottom line for both Bio-Techne and its customers.
These innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. Leveraging generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design, Bio-Techne's expanded portfolio delivers next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability.
"Our growing portfolio of designer proteins combine cutting-edge AI technology and innovative protein engineering," said Will Geist, President, Protein Sciences Segment. "This expanded portfolio empowers our customers with versatile, high-performance solutions to boost the production of immune cells and enhance regenerative medicine cell therapies. Bio-Techne remains committed to developing the tools and workflow solutions our customers need to advance innovative cell therapies in both clinical and research settings."
The new products include:
- IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor-infiltrating lymphocytes (TIL) expansion.
- Activin A Hyperactive: Optimized for superior performance in regenerative medicine cell differentiation applications.
- FGF basic Heat Stable: A robust and versatile growth factor designed for improved protein stability and performance for stem cell culture applications, available in both RUO and GMP formats to support cell therapy manufacturing and advanced research.
- Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonists: Key reagents for advancing stem cell research, organoid development, and regenerative medicine.
With this expanded portfolio, Bio-Techne continues to lead the way in delivering disruptive innovations to the life sciences and therapeutic development communities. Bio-Techne designer proteins are available as part of our market leading R&D Systems branded portfolio of proteins. For more information about these AI Modified Proteins, visit our website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-rd-systems-ai-engineered-designer-protein-portfolio-to-advance-cell-therapy-and-regenerative-medicine-302347098.html
SOURCE Bio-Techne Corporation
FAQ
What new AI-engineered proteins has Bio-Techne (TECH) launched in January 2024?
How are Bio-Techne's (TECH) new designer proteins engineered?
What are the key applications for Bio-Techne's (TECH) new designer proteins?
What enhanced functionalities do Bio-Techne's (TECH) new designer proteins offer?
